To the Editor We read with great interest the article by Chu et al¹ that describes the association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer. We agree with the authors that there are limitations to the study. Furthermore, together in viewing the previous publication regarding the same population,² we believe that the study raised an issue regarding the difference in response to treatment with anti–human epidermal growth factor receptor 2 (HER2) drugs among cancer patients of different ethnic groups.

中文翻译：

---

影响质子泵抑制剂与卡培他滨在晚期胃食管癌中疗效关联的因素

致编辑我们非常感兴趣地阅读了 Chu 等人¹的文章，该文章描述了质子泵抑制剂与卡培他滨在晚期胃食管癌中疗效的关系。我们同意作者的观点，即这项研究存在局限性。此外，在查看之前关于同一人群的出版物²时，我们认为该研究提出了一个问题，即不同种族癌症患者对抗人表皮生长因子受体 2 (HER2) 药物治疗的反应差异。